Increased Prevalence of Antibodies to Hepatitis E Virus in Patients with Neurocysticercosis

We explored the association between serological status for hepatitis E and neurocysticercosis (NCC) in neurologic patients attending a national neurological referral center in Lima, Perú, between the years 2008 and 2012. Anti-hepatitis E antibodies were evaluated in patients with and without NCC, an...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of tropical medicine and hygiene Vol. 110; no. 6; pp. 1210 - 1213
Main Authors Abanto, Jesus, Sanchez Boluarte, Arantxa N., Castillo, Yesenia, Perez, Erika, Saavedra, Herbert, Gonzales, Isidro, Bustos, Javier A., Abravanel, Florence, Izopet, Jacques, Madden, Richie G., Garcia, Hector H., Dalton, Harry R.
Format Journal Article
LanguageEnglish
Published United States Institute of Tropical Medicine 05.06.2024
American Society of Tropical Medicine and Hygiene
The American Society of Tropical Medicine and Hygiene
Subjects
Adolescent
Adult
Aged
Antibodies
Female
Hepatitis
Hepatitis Antibodies
Hepatitis Antibodies - blood
Hepatitis E
Hepatitis E - epidemiology
Hepatitis E - immunology
Hepatitis E virus
Hepatitis E virus - immunology
Humans
Immunoglobulin G
Immunoglobulin G - blood
Life Sciences
Male
Middle Aged
Neurocysticercosis
Neurocysticercosis - complications
Neurocysticercosis - epidemiology
Neurocysticercosis - immunology
Neurological disorders
Patients
Peru
Peru - epidemiology
Prevalence
Seroepidemiologic Studies
Short Report
Young Adult
Peru
Online AccessGet full text

Cover

More Information
Summary:We explored the association between serological status for hepatitis E and neurocysticercosis (NCC) in neurologic patients attending a national neurological referral center in Lima, Perú, between the years 2008 and 2012. Anti-hepatitis E antibodies were evaluated in patients with and without NCC, and a control group of rural general population. Anti-hepatitis E IgG was found in 23.8% of patients with NCC, compared with 14.3% in subjects without NCC from a general rural population ( P = 0.023) and 14.4% in subjects with neurological complaints without NCC ( P = 0.027). Seropositive patients had a median age of 44 years compared with 30 years in seronegative patients ( P <0.001). No significant differences in sex, region of residence, or liver enzyme values were found. Seropositivity to hepatitis E was frequent in this Peruvian population and higher in patients with NCC, suggesting shared common routes of infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMCID: PMC11154044
Disclosure: The authors certify that they have no affiliations with or involvement in any entity with any financial interest.
Authors’ addresses: Jesus Abanto, Department of Neurology, University of Cincinnati, Cincinnati, OH, and Center for Global Health, Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru, E-mail: abantojs@ucmail.uc.edu. Arantxa N. Sanchez Boluarte, Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru, and Department of Global Health, University of Washington, Seattle, WA, E-mail: aransb21@uw.edu. Yesenia Castillo, Center for Global Health, Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru, E-mail: yesenia.castillo.b@upch.pe. Erika Perez, Isidro Gonzales, and Herbert Saavedra, Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru, E-mails: erika.perez.p@upch.pe, isidrogonzalesq@hotmail.com, and hsaavedrapastor@hotmail.com. Javier A. Bustos and Hector H. Garcia, Center for Global Health, Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru, and Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru, E-mails: jbustos@jhsph.edu and hgarcia@jhsph.edu. Florence Abravanel and Jacques Izopet, Laboratoire de Virologie, CHU Purpan, Toulouse, France, E-mails: abravanel.f@chu-toulouse.fr and izopet.j@chu-toulouse.fr. Richie G. Madden and Harry R. Dalton, Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, University of Adelaide, Australia, and HEV International Direct Action Group, E-mails: richie@forfey.com and hardalton@gmail.com.
Financial support: Beijing Wantai Biological donated the ELISA kits for detection of IgG and IgM antibodies against HEV used in this study. J. Abanto is partially supported by FIC NIH training grant TW001140.
ISSN:0002-9637
1476-1645
1476-1645
DOI:10.4269/ajtmh.23-0856